WHAT IS CLAIMED IS:

1. Use of benralizumab in the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, wherein a dose of the medicament comprising 30 mg of benralizumab is to be administered to the patient with three four-week dosing intervals and then at eight-week dosing intervals.

2. The use of claim 1, wherein the patient has a blood eosinophil count of at least 200 eosinophils/μL prior to the administration.

3. The use of claim 2, wherein the patient has a blood eosinophil count of at least 300 eosinophils/μL prior to the administration.

4. The use of claim 3, wherein the patient has a blood eosinophil count of at least 400 eosinophils/μL prior to the administration.

5. The use of any one of claims 1-4, wherein the patient has severe or very severe COPD as defined by Global Initiative for Chronic Obstructive Lung Disease (GOLD).

6. The use of any one of claims 1-5, wherein the administration reduces the exacerbation rate of COPD in the patient.

7. The use of any one of claims 1-6, wherein the administration increases the patient's FEV_1.

8. The use of any one of claims 1-7, wherein the administration increases the patient's FVC.

9. The use of any one of claims 1-8, wherein the administration improves a COPD questionnaire score assessing COPD symptoms in the patient.

10. The use of any one of claims 1-9, wherein the patient uses corticosteroids, long-acting β2 agonists, and tiotropium.

11. The use of any one of claims 1-10, wherein the administration is subcutaneous.